NVS vs. SNY

Last updated Apr 2, 2026

Compare and contrast key facts about Novartis AG (NVS) and Sanofi (SNY).

Performance

NVS vs. SNY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novartis AG (NVS) and Sanofi (SNY). The values are adjusted to include any dividend payments, if applicable.

NVS vs. SNY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NVS Novartis AG	15.91%	46.95%	0.02%	16.14%	8.06%	-3.65%	3.34%	13.92%	5.95%	19.42%
SNY Sanofi	-1.51%	4.93%	1.09%	6.55%	0.57%	7.00%	0.39%	20.47%	6.06%	9.96%

Fundamentals

Market Cap NVS : $299.15B SNY : $116.50B
EPS NVS : $7.20 SNY : $3.18
PE Ratio NVS : 21.55 SNY : 15.02
PS Ratio NVS : 5.37 SNY : 2.51
PB Ratio NVS : 6.48 SNY : 1.63
Total Revenue (TTM) NVS : $56.15B SNY : $46.72B
Gross Profit (TTM) NVS : $41.12B SNY : $33.79B
EBITDA (TTM) NVS : $22.99B SNY : $12.68B

Returns By Period

In the year-to-date period, NVS achieves a 15.91% return, which is significantly higher than SNY's -1.51% return. Over the past 10 years, NVS has outperformed SNY with an annualized return of 12.09%, while SNY has yielded a comparatively lower 5.86% annualized return.

NVS

• 1D: 1.53%
• 1M: -4.24%
• YTD: 15.91%
• 6M: 21.32%
• 1Y: 45.79%
• 3Y*: 23.19%
• 5Y*: 16.79%
• 10Y*: 12.09%

SNY

• 1D: -0.93%
• 1M: 0.15%
• YTD: -1.51%
• 6M: -4.08%
• 1Y: -8.27%
• 3Y*: -0.31%
• 5Y*: 3.35%
• 10Y*: 5.86%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NVS vs. SNY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVS

NVS Risk / Return Rank: 90
NVS Sharpe Ratio Rank: 91
NVS Sortino Ratio Rank: 89
NVS Omega Ratio Rank: 87
NVS Calmar Ratio Rank: 90
NVS Martin Ratio Rank: 91

SNY

SNY Risk / Return Rank: 23
SNY Sharpe Ratio Rank: 27
SNY Sortino Ratio Rank: 24
SNY Omega Ratio Rank: 24
SNY Calmar Ratio Rank: 22
SNY Martin Ratio Rank: 20

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NVS vs. SNY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NVS) and Sanofi (SNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NVS	SNY	Difference
Sharpe ratio Return per unit of total volatility	2.13	-0.30	+2.43
Sortino ratio Return per unit of downside risk	2.74	-0.23	+2.97
Omega ratio Gain probability vs. loss probability	1.36	0.97	+0.39
Calmar ratio Return relative to maximum drawdown	4.03	-0.57	+4.59
Martin ratio Return relative to average drawdown	11.81	-1.12	+12.92
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NVS vs. SNY - Sharpe Ratio Comparison

The current NVS Sharpe Ratio is 2.13, which is higher than the SNY Sharpe Ratio of -0.30. The chart below compares the historical Sharpe Ratios of NVS and SNY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NVS	SNY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.13	-0.30	+2.43
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.91	0.14	+0.77
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.62	0.25	+0.37
Sharpe Ratio (All Time) Calculated using the full available price history	0.43	0.21	+0.22

Correlation

The correlation between NVS and SNY is 0.55, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

NVS vs. SNY - Dividend Comparison

NVS's dividend yield for the trailing twelve months is around 3.08%, less than SNY's 4.63% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NVS Novartis AG	3.08%	2.90%	3.84%	3.44%	3.70%	3.86%	3.22%	3.03%	3.47%	3.24%	3.73%	3.10%
SNY Sanofi	4.63%	4.56%	4.22%	3.83%	4.32%	3.80%	3.61%	3.47%	4.29%	3.82%	4.11%	3.77%

Drawdowns

NVS vs. SNY - Drawdown Comparison

The maximum NVS drawdown since its inception was -42.10%, smaller than the maximum SNY drawdown of -46.46%. Use the drawdown chart below to compare losses from any high point for NVS and SNY.

Drawdown Indicators

	NVS	SNY	Difference
Max Drawdown Largest peak-to-trough decline	-42.10%	-46.46%	+4.36%
Max Drawdown (1Y) Largest decline over 1 year	-10.76%	-17.87%	+7.11%
Max Drawdown (5Y) Largest decline over 5 years	-20.42%	-33.52%	+13.10%
Max Drawdown (10Y) Largest decline over 10 years	-26.03%	-33.52%	+7.49%
Current Drawdown Current decline from peak	-5.23%	-16.11%	+10.88%
Average Drawdown Average peak-to-trough decline	-10.94%	-12.15%	+1.21%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.67%	9.06%	-5.39%

Volatility

NVS vs. SNY - Volatility Comparison

The current volatility for Novartis AG (NVS) is 6.44%, while Sanofi (SNY) has a volatility of 6.79%. This indicates that NVS experiences smaller price fluctuations and is considered to be less risky than SNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NVS	SNY	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.44%	6.79%	-0.35%
Volatility (6M) Calculated over the trailing 6-month period	14.50%	16.85%	-2.35%
Volatility (1Y) Calculated over the trailing 1-year period	21.68%	27.50%	-5.82%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	18.52%	24.65%	-6.13%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	19.55%	23.51%	-3.96%

Financials

NVS vs. SNY - Profitability Comparison

The chart below illustrates the profitability comparison between Novartis AG and Sanofi over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NVS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novartis AG reported a gross profit of 8.40B and revenue of 13.33B. Therefore, the gross margin over that period was 63.0%.

SNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Sanofi reported a gross profit of 8.58B and revenue of 12.21B. Therefore, the gross margin over that period was 70.3%.

NVS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novartis AG reported an operating income of 3.05B and revenue of 13.33B, resulting in an operating margin of 22.8%.

SNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Sanofi reported an operating income of -1.04B and revenue of 12.21B, resulting in an operating margin of -8.5%.

NVS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novartis AG reported a net income of 2.41B and revenue of 13.33B, resulting in a net margin of 18.1%.

SNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Sanofi reported a net income of -801.00M and revenue of 12.21B, resulting in a net margin of -6.6%.